79.61

1.35% 1.06

After Hours: 79.61

Dianthus Therapeutics Inc (DNTH)

Overview News Price History Financials Discussions Forecast

Dianthus Therapeutics Inc stock is traded at $79.61, with a volume of 1.03M. It is up +1.35% in the last 24 hours and up +53.48% over the past month. Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Previous Close:

$78.55

Open:

$78.94

24h Volume:

1.03M

Relative Volume:

1.03

Market Cap:

$4.21B

Revenue:

$2.04M

Net Income/Loss:

$-162.34M

P/E Ratio:

-19.36

EPS:

-4.1129

Net Cash Flow:

$-129.27M

1W Performance:

+0.95%

1M Performance:

+53.48%

6M Performance:

+122.13%

1Y Performance:

+335.27%

1-Day Range:

$78.94

$82.14

1-Week Range:

$75.50

$82.49

52-Week Range:

$13.37

$88.02

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name

Dianthus Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

929-999-4055

Address

7 TIMES SQUARE, NEW YORK

Employee

Twitter

Next Earnings Date

2026-03-10

Latest SEC Filings

DNTH's Discussions on Twitter

Compare DNTH vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNTH Dianthus Therapeutics Inc	79.61	4.16B	2.04M	-162.34M	-129.27M	-4.1129
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-26	Upgrade	Raymond James	Outperform → Strong Buy
Oct-14-25	Initiated	Truist	Buy
Jul-02-25	Initiated	William Blair	Outperform
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform
Jul-26-24	Initiated	Robert W. Baird	Outperform
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy
Feb-15-24	Initiated	Stifel	Buy
Dec-26-23	Initiated	Jefferies	Buy
Nov-22-23	Initiated	Wedbush	Outperform
Oct-30-23	Initiated	Guggenheim	Buy
Sep-28-23	Initiated	Raymond James	Outperform
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-06-22	Upgrade	Goldman	Neutral → Buy
Aug-20-21	Resumed	Goldman	Neutral
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-22-21	Reiterated	B. Riley Securities	Buy
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight
Jun-15-21	Initiated	BTIG Research	Buy
May-18-21	Initiated	B. Riley Securities	Buy
Jan-07-21	Initiated	Mizuho	Buy
Jun-08-20	Upgrade	Goldman	Neutral → Buy
Mar-25-19	Downgrade	Goldman	Buy → Neutral
Mar-15-19	Initiated	Raymond James	Outperform

View All

Dianthus Therapeutics Inc Stock (DNTH) Latest News

Mar 24, 2026

[144] Dianthus Therapeutics, Inc.... | DNTH SEC FilingForm 144 - Stock Titan

Mar 24, 2026

Mar 23, 2026

Wedbush keeps outperform on Dianthus Therapeutics, Inc. (DNTH), highlights potential of Claseprubart in CIDP - MSN

Mar 23, 2026

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit - AOL.com

Mar 23, 2026

Mar 22, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 22, 2026

Mar 21, 2026